Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
18 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
06 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st...
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 08h15 HE
|
Interpace Diagnostics Group, Inc.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...
Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®
29 juil. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Four Million Members Gain in-Network Access PARSIPPANY, NJ, July 29, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has entered in to a contract...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
09 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
06 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
01 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
17 déc. 2018 06h50 HE
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...
Interpace Diagnostics Announces Participation at the DJCON18
24 oct. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
Including Participation in the Panel on the Impact of AI and Bioinformatics in Healthcare PARSIPPANY, NJ, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
31 juil. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 31, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...